創新疫苗引擎持續驅動 康希諾開啟新增長週期

香港,2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 2025年上半年,醫藥行業結構性轉型持續深化,在政策利好、產品升級與技術革新的共同推動下,疫苗產業呈現出穩中向好的發展態勢。作為中國創新疫苗領域的領軍企業,康希諾生物(上交所代碼:688185.SH,聯交所代碼:6185.HK)再度交出一份穩健發展的成績單。根據2025年半年度業績公告,康希諾在今年上半年實現收入3.82億元人民幣,同比增長26%,營收持續向上;儘管尚未實現全面扭虧,但虧損幅度已顯著收窄,收窄幅度同比超過94%,經營質量進一步提升,為全年穩健增長奠定了堅實基礎。而隨著旗下核心產品銷售勢頭強勁,以及多個在研管線穩步推進,康希諾的長期成長邏輯正逐步兌現。流腦疫苗組合持續放量,釋放增長動能康希諾目前在售的兩款流腦結合疫苗——四價流腦結合疫苗曼海欣(MCV4)和二價流腦結合疫苗美奈喜(MCV2),是公司業績的核心支柱。尤其MCV4的持續放量展現出強勁的市場競爭力,並構成了公司核心的成長邏輯。曼海欣和美奈喜兩款疫苗在2024年便已實現銷售收入近8億元,同比增長超40%。今年上半年,在渠道深化與終端滲透率提升的推動下,兩款疫苗的銷量繼續保持穩中有進的良好增長態勢。2025年上半年,公司的流腦疫苗組合實現銷售額超3.64億元,同比增長超過38%,為業績提供了堅實基礎。其中,曼海欣作為國內唯一獲批上市的四價流腦結合疫苗,憑藉其有效覆蓋ACYW135四種腦膜炎球菌血清型,以及採用高安全性CRM197載體技術帶來的技術優勢,在臨床免疫原性與安全性方面表現出色,已成為眾多家長為孩子接種流腦疫苗的首選。不僅如此,曼海欣的市場潛力還在進一步釋放。目前,該疫苗已向國家藥監局提交擴齡申請,適應人群擬由"3月齡至3周歲(47月齡)"兒童擴大至"3月齡至6周歲(83月齡)"兒童。若順利獲批,將直接拓寬其接種人群覆蓋面,增強其在非免疫規劃市場中的滲透力,為康希諾未來兩到三年的持續增長注入確定性動力,進一步鞏固公司在流腦疫苗領域的領先地位。優佩欣正式上市,打造差異化肺炎疫苗新標桿今年6月,康希諾自主研發的重磅新品——13價肺炎結合疫苗優佩欣(PCV13i)正式獲批上市,標誌著公司成功進軍百億級肺炎疫苗市場,邁入了新一輪增長周期。肺炎球菌性疾病是全球嚴重的公共衛生問題,尤其在5歲以下兒童中致病率和致死率極高。面對國內尚存的免疫防護缺口,優佩欣的上市填補了本土高端13價肺炎結合疫苗的技術空白,也展現出康希諾在差異化創新路徑上的領先優勢。與市場上現有的同類疫苗相比,優佩欣在三大維度實現突破。首先是防護更為精準,該款疫苗主要針對佔中國兒童肺炎球菌病超60%的19F、19A、7F、3型四大高危血清型,臨床試驗數據顯示其抗體幾何平均濃度(GMC)顯著優於競品。其次是在載體技術層面上,採用全球首創的CRM197+TT雙載體技術,突破單載體疫苗的免疫干擾瓶頸,既降低與其他疫苗共注射時的免疫抑制風險,又顯著提升免疫原性。最後是其工藝的安全性,優佩欣採用的是無動物源發酵工藝,降低了動物源生物因子造成的風險,同時在生產過程中無甲醛脫毒、無苯酚添加,顯著提升疫苗的安全性。這三重優勢,使優佩欣有望成為繼曼海欣之後,康希諾在嬰幼兒細菌性疫苗市場上的又一張"王牌"。值得關注的是,優佩欣的目標人群與曼海欣高度重合,渠道協同效應將加速其商業化進程,並將幫助公司在超百億規模的肺炎疫苗市場中快速搶佔份額。多聯多價疫苗戰略穩步推進不止於此,康希諾的長期潛力更體現在其持續構建的"多聯多價疫苗"產品矩陣上。相比傳統單價疫苗,多聯多價疫苗可在一次注射中同時預防多種疾病,極大提升接種效率與接種意願,代表著全球疫苗技術發展的主流方向。繼四價疫苗曼海欣和多價疫苗優佩欣之後,康希諾的DTcP-Hib-MCV5五聯苗作為多聯疫苗的代表,研發進展備受市場關注。今年2月,該疫苗獲得了臨床試驗批准,這也意味著公司在高端聯合疫苗領域實現"零的突破"。DTcP-Hib-MCV5五聯苗可同時預防百日咳、白喉、破傷風、b型流感嗜血桿菌病和流腦四大血清群感染,實現"一針防五病",顯著減少接種次數,提升嬰幼兒接種依從性。更重要的是,這款疫苗的核心組分MCV4(即曼海欣)已在國內完成商業化驗證,並具備良好口碑,為聯合疫苗的開發提供了強力支撐。這種"由點及面"的產品升級邏輯,使得康希諾在聯合疫苗市場的推進更具效率和信心。疊加國家對於多聯疫苗研發的高度重視與政策扶持,康希諾有望藉此搶佔多聯多價疫苗這一市場高地。研發驅動+梯隊清晰,管線儲備豐富在鞏固既有市場優勢的同時,康希諾持續通過強勁的研發能力和差異化的管線佈局,夯實中長期增長動能。嬰幼兒組分百白破疫苗已進入優先審評,有望填補國內空白;青少年及成人百白破疫苗完成III期臨床受試者入組,實現全生命周期覆蓋;破傷風疫苗註冊申請獲受理,預期該疫苗較現有產品在安全性和免疫原性數據上更具優勢;重組脊髓灰質炎疫苗獲蓋茨基金會資助並在印尼啟動臨床,並在國內獲得臨床試驗批准;全球創新的重組肺炎蛋白疫苗、吸入式結核病加強疫苗也已進入臨床研究階段並驗證概念。可以看到,公司目前已構建起涵蓋腦膜炎球菌疫苗、肺炎球菌疫苗、百白破疫苗、脊灰疫苗、結核病疫苗、帶狀皰疹疫苗等多技術路徑和全生命周期段的豐富研發管線,多個重磅品種正在進入註冊審評或臨床試驗關鍵階段。同時,公司在關鍵技術平台上的不斷實現自主突破,這種持續的創新能力支撐著公司從單一產品突破到管線持續輸出的戰略躍遷。總體而言,康希諾在2025年上半年延續了2024年以來的良好增長勢頭,印證其從產品研發到商業化的閉環能力已日趨成熟。在國家政策持續支持創新疫苗,支持國產高端疫苗替代的大背景下,康希諾憑藉其深厚的研發底蘊、差異化管線佈局和高效的商業化執行力,正加速兌現其長期成長潛力,向全球創新疫苗領軍者不斷邁進。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
亨得利2025年中期業績發佈 堅持行穩致遠 保生存謀發展 ACN Newswire

亨得利2025年中期業績發佈 堅持行穩致遠 保生存謀發展

香港,2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 亨得利控股有限公司(「亨得利」或「公司」及其子公司「集團」,股票代號:3389)宣佈截至2025年6月30日止6個月(「回顧期內」)之中期業績。2025年上半年,全球環境依舊錯綜複雜,貿易壁壘增加、貿易摩擦加劇、地緣政治衝突等不確定性因素使全球經濟增長動能偏弱。中國經濟增速在內外多重挑戰中有所放緩,但仍實現穩定增長,體現了中國經濟的韌性,穩中向好的態勢得以繼續。面對複雜多變的經營環境,本集團以「行穩致遠」為準則,順應市場調整業務,保生存、求發展,努力維護股東的利益。回顧期內,本集團收入錄得314,314,000元(人民幣,下同;2024年6月30日止六個月為580,361,000元),較去年同期下降了45.8%;高端消費配套業務等收入為248,095,000元(2024年6月30日止六個月為352,339,000元),較去年同期下降了29.6%;大宗商品貿易收入為66,219,000元(2024年6月30日止六個月為228,022,000元),較去年同期下降了71.0%。於回顧期,本集團錄得溢利,溢利額為26,033,000元(截至2024年6月30日六個月溢利: 499,000元),較去年同期上升了5,117.0%;而股份持有人應佔溢利為26,308,000元(截至2024年6月30日六個月虧損:2,504,000元),較去年同期上升了1,150.6%。盈利的主要原因是匯率波動導致營運單位產生外匯兌換收益。回顧期內,面臨國際市場不確定性及國內經濟增長放緩,本集團高端消費配套業務發展持續承壓。集團採取多種措施應對複雜的經營環境,通過創新的方式,不斷拓寬業務模式,拓展新客戶,開發新產品。同時,提升技術創新水準,加快了機械化步伐;規範和加強資訊化及自動化管理。各項措施均取得了成效,提升應對風險的能力。回顧期內,由於經營環境因素影響,高端消費配套業務的銷售業績及利潤與去年同比均有所下降。國際貿易方面,回顧期內,本集團根據既定戰略繼續開展國際大宗商品貿易業務。業務範圍主要涵蓋鐵礦石、動力煤及焦煤向中國內地的進口。由於貿易摩擦衝擊經濟前景,全球鐵礦石需求增速放緩,價格疲軟。受礦砂銷售價格的波動下降及客戶購買意願減弱等因素的影響,國際大宗商品貿易業務之銷售額及毛利較去年同期均有所下滑,但仍然維持了正面營收。集團計劃於墨西哥建設的一個集清關、進口、運輸、倉儲於一體的大宗貨物中轉物流園區,已經與多個中國大型企業與上市公司展開合作並提供服務。下半年,集團將繼續緊跟市場動態,適時而謹慎地開展國際大宗商品貿易活動,尋求新的盈利模式和未來發展方向,為集團的健康生存與發展奠定堅實基礎。國際海運方面,回顧期內,集團國際海運業務主要專注於全球大宗乾散貨物的海洋運輸,貨種涵蓋煤炭、鐵礦石、錳礦石、鋁釩土、糧食及工業鹽等大宗貨物,服務的客戶包括國際知名礦山和中國大型中央企業及上市公司等。回顧期內,全球乾散貨航運市場波動大,運價受到影響。集團緊貼市場行情,繼續拓展業務,努力發展新客戶,與客戶致力於簽訂長航次運輸合同,為公司鎖定長期利潤。上半年,受市場波動的影響,集團海運業務收入與利潤均出現下滑。當前,國際政治、經濟環境動盪不安因素加劇,貿易壁壘和貿易摩擦形勢嚴峻。面對嚴峻的外部環境,中國內地經濟也面臨一定的困難和挑戰,需求端不足,消費端有待提振,結構性調整仍在持續。然而,中國內地經濟基礎穩、韌性強、潛能大,長期向好的發展趨勢未發生改變。隨著中國政府各項政策措施的實施與完善,對未來中國內地經濟長期持續發展態勢仍然充滿信心。下半年,本集團將堅持「行穩致遠、持續經營」之原則,依託中國內地「穩中求進、以進促穩」的經濟環境,緊貼市場,謹慎而穩妥地持續推進國際貿易業務,並不斷擴展與國際貿易密切相關的海運業務,力爭成為國際海運供應鏈中的重要一員,為企業的突破性發展提供助力。集團亦將順應市場需求,面向中國內地和國際雙市場,不斷提升商業空間一體化服務水準。我們將調整高端名表配套產品的生產,同時推進有限多元化業務,拓展高端消費配套生產至其他高端生活品領域,如珠寶、眼鏡、化妝品、手機及其他3C產品,並將商業空間美化服務擴展至生活空間美化服務,從而在高端消費配套生態鏈中成為不可或缺的獨立環節。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
英皇鐘錶珠寶公佈2025年中期業績 來自香港及中國內地之收入分別上升9% ACN Newswire

英皇鐘錶珠寶公佈2025年中期業績 來自香港及中國內地之收入分別上升9%

業績摘要- 本期間的總收入上升8%至28億港元,其中來自香港的收入上升9%至16億港元,而來自中國內地的收入上升9%至7億港元,兩地均錄得增長- 珠寶分部的收入顯著上升13%至11億港元,當中黃金產品佔珠寶分部的收入超過7成半- 毛利增加8%至8億港元;毛利率為30.1%,表現呈抗跌力- 經調整EBITD1上升至3億港元,淨利潤增加5%至2億港元- 於2025年6月30日,銀行結餘及手頭現金為超過15億港元(2024年12月31日:9.5億港元),沒有任何銀行借貸,並處於淨現金狀況,因此淨負債比率為零,反映財務狀況非常健康- 成功夥拍陳世昌先生,致力擴展「英皇珠寶」於中國內地之珠寶業務,並已擬定初步開店路線圖,初期目標是於未來五年分階段於中國內地開設600間店舖。在其具韌性的鐘錶業務基礎上,務求珠寶業務成為未來增長動力- 於香港中環黃金地段開設了一間百達翡麗旗艦店,進一步鞏固市場地位香港,2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 歐洲製鐘錶及珠寶首飾之零售商翹楚-英皇鐘錶珠寶有限公司(「本集團」或「英皇鐘錶珠寶」)(股份編號:887)公佈其截至2025年6月30日止六個月(「本期間」)之中期業績。縱使市場存在不明朗因素及營商環境充滿挑戰,本集團於本期間的總收入增加7.6%至27.9億港元(2024年:26.0億港元)。來自香港的收入增加8.8%至15.9億港元(2024年:14.7億港元),佔總收入57.1%(2024年:56.4%),而來自中國內地的收入增加8.7%至7.2億港元(2024年:6.7億港元),佔總收入25.9% (2024年:25.6%)。按產品分部劃分的收入而言,鐘錶分部的收入上升4.2%至17.0億港元(2024年:16.3億港元),佔總收入60.8% (2024年:62.8%),而珠寶分部的收入顯著增加13.4%至10.9億港元(2024年:9.7億港元),佔總收入39.2% (2024年:37.2%),當中黃金產品佔珠寶分部的收入約75.2% (2024年:77.0%)。本集團的毛利增加7.7%至8.4億港元(2024年:7.8億港元),毛利率為30.1% (2024年:30.0%),表現呈抗跌力。本集團於本期間的淨利潤增加4.9%至1.94億港元(2024年:1.85億港元)。每股基本盈利為2.73港仙(2024年:2.72 港仙)。董事會宣派中期股息每股0.55港仙(2024年:0.65 港仙)。於2025年6月30日,本集團之銀行結餘及手頭現金為15.1億港元(2024年12月31日:9.5億港元),沒有任何銀行借貸(2024年12月31日:零)並處於淨現金狀況,因此淨負債比率為零(2024年12月31日:零),顯示健康的財務狀況。於本期間,本集團就其於中國內地珠寶業務之策略性發展成功夥拍陳世昌先生(「陳先生」)。陳先生為一位於珠寶行業具影響力且備受推崇的資深人士,擁有超過40年的經驗。本集團已初步擬定於中國內地擴展店舖的路線圖,初期目標是於未來五年分階段開設600 間店舖。於第一階段,開店的重點會落在成熟的一線城市及新一線城市,面向中高端市場;後續開店將側重於二線城市,面向中端市場。於2025年6月30日,本集團於香港、澳門、中國內地、新加坡及馬來西亞營運共73間店舖。於本期間,本集團於香港及澳門新開設兩間珠寶店,另外亦分別於香港及中國內地重慶開設一間百達翡麗旗艦店及一間帝舵表鐘錶專賣店。本期間後,本集團於中國杭州開設一間珠寶店。英皇鐘錶珠寶主席楊諾思女士表示︰「隨著深圳戶籍居民一簽多行個人遊計劃恢復後人流持續回升,加上香港政府推行的旅遊業藍圖,本集團有信心整體零售市場將進一步重拾增長動力。本集團近期於香港開業的百達翡麗旗艦店,將進一步提升本集團於名貴鐘錶零售市場的競爭優勢,並鞏固其市場領先地位。」楊女士總結道︰「鑒於物業及股票市場波動,本集團預期作為另類投資的黃金珠寶將繼續受中國消費者歡迎。本集團認為與陳先生建立戰略合作夥伴關係,將為擴展其於中國內地之珠寶業務帶來寶貴機會。我們將以多元化市場細分策略,有效地擴大其零售網絡佈局,從而在中國內地市場的龐大商機中搶佔重大份額。」財務亮點 截至6月30日止六個月變動2024年百萬港元2025年百萬港元總收入2,5972,794+ 7.6%毛利780840+ 7.7%毛利率30.0%30.1%+ 0.1百份點經調整EBITD [1]282297+ 5.3%淨利潤185194+ 4.9%每股基本盈利2.72港仙2.73港仙+ 0.4%[1] 經調整EBITD為利息、稅項及自家擁有旗艦店的折舊費用前之盈利,以反映本集團之核心營運表現關於英皇鐘錶珠寶有限公司作為零售商翹楚,英皇鐘錶珠寶(887.HK)自1942年在香港開業至今已有超過80年悠久歷史,業務包括銷售享譽國際之歐洲製腕錶及旗下「英皇珠寶」品牌之珠寶首飾。憑藉其代理齊全的鐘錶品牌、獨特的市場推廣策略以及遍佈香港、澳門、中國內地、新加坡及馬來西亞黃金地段的廣泛零售網絡,英皇鐘錶珠寶在全球各地中高收入人士的目標顧客群中已建立穩固的品牌形象。於香港投資者關係協會頒發的2025年香港投資者關係大獎中,英皇鐘錶珠寶榮獲「最佳投資者關係公司-小型股」、「最佳投資者關係團隊-小型股」及「最佳投資者關係素材-小型股」。有關詳細資料,請瀏覽其網站︰www.EmperorWatchJewellery.com。投資者/媒體查詢陸文靜集團投資者關係總監電話︰+852 2835 6783電郵:annaluk@emperorgroup.com區雪瑩集團投資人關係經理電話︰+852 2835 6799電郵:janiceau@emperorgroup.com Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Rust Mobile首次封閉測試定於11月開啟 ACN Newswire

Rust Mobile首次封閉測試定於11月開啟

深圳, 2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 在本月早些時候備受期待的全球首秀之後,Level Infinite 將於11月初開啟《Rust Mobile》首次封閉測試。玩家們可以在 2025 年 8 月 20 日至 24 日於科隆舉辦的 gamescom 上,率先親身體驗這款遊戲。《Rust Mobile》將經典的開放世界生存玩法完整呈現,並針對行動裝置進行了優化,讓數百萬粉絲熟悉並熱愛的體驗隨時隨地都能上手。本作由 Facepunch Studios 官方授權,在忠實還原原作精神的同時,也為行動端帶來全新的生存方式。從收集資源、建造堅固基地,到殘酷的 PvP 戰鬥,以及伴隨信任與背叛而來的緊張氛圍,行動版完整呈現了《Rust》的核心精髓。玩家不僅能夠在 gamescom 上率先感受遊戲的魅力,還可透過即將到來的封閉測試進一步體驗其獨特樂趣。《Rust Mobile》亮相 2025 科隆遊戲展參展觀眾可前往 06.1 展館 - C-051G 展位,在這裡親身體驗遊戲,並參與一系列將《Rust》世界帶入現實的特色活動。活動包括與主題道具互動、沉浸式感受展位環境等。每位參與者都將獲得一次轉動「戰利品轉盤」的機會,有機會贏取 2025 科隆遊戲展獨家紀念品,包括限量版海報和環保袋。首次封閉測試將於今年11月開啟《Rust Mobile》首次封閉測試將於 2025 年 11 月初上線,屆時將邀請來自北美、西歐及部分亞洲地區的 30,000 名玩家參與。本次測試將提供四種語言版本:英語、日語、繁體中文和泰語,並支援 iOS、Android 及平板裝置,確保玩家能夠在自己熟悉的平台上暢玩遊戲。封閉測試現已開放註冊,玩家可前往 www.rustmobile.com 報名。欲了解更多有關《Rust Mobile》的資訊或進行預註冊,請訪問 rustmobile.com,或關注遊戲的 X 帳號與 YouTube 頻道。有關科隆遊戲展開館時間,請訪問 www.gamescom.global 。關於 Level InfiniteLevel Infinite 是騰訊旗下的全球遊戲品牌,致力於隨時隨地為全球玩家帶來引人入勝且獨具特色的遊戲體驗。該品牌還為全球範圍內的開發者和合作工作室提供多種服務與資源,幫助他們釋放遊戲潛力。Level Infinite 既是《PUBG MOBILE》《王者榮耀》《勝利女神:NIKKE》等爆款遊戲的發行商,也是《沙丘:覺醒》(Funcom 開發)、《戰鎚40K:Darktide》等眾多遊戲的深度合作夥伴。欲了解更多關於 Level Infinite 的資訊,請訪問 www.levelinfinite.com 。聯絡資訊Kirsty EndfieldSwipe Right PRtencent@swiperight.gg來源: Level Infinite Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Spritzer Sparkling Adds a Fizzy Twist to Merdeka and Hari Malaysia 2025 with “Kasi Sparkling, Baru Kick!” ACN Newswire

Spritzer Sparkling Adds a Fizzy Twist to Merdeka and Hari Malaysia 2025 with “Kasi Sparkling, Baru Kick!”

A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins ACN Newswire

Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Champion REIT Announces 2025 Interim Results ACN Newswire

Champion REIT Announces 2025 Interim Results

- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.
More
uSMART Group Accelerates Expansion with 12 New Branches ACN Newswire

uSMART Group Accelerates Expansion with 12 New Branches

HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
More
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers ACN Newswire

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
冠君產業信託公佈2025年度中期業績 ACN Newswire

冠君產業信託公佈2025年度中期業績

- 朗豪坊商場開業20周年「立足本地,引領全球潮流文化」,成品牌進駐熱點,Chiikawa拉麵首間海外分店掀熱潮- 花園道三號於2025年到期的租約已全部處理,續約率維持在高水平- 朗豪坊辦公樓推出結合六大健康維度「6D Wellness」的創新概念,強化其一站式身心健康及生活時尚總匯的市場定位- 香港銀行同業拆息下降節省利息開支,2025年債務成功全額再融資香港,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 持有花園道三號及朗豪坊物業的冠君產業信託(股份代號:2778)公布截至 2025 年 6 月 30 日止的中期業績。業績摘要 2025上半年2024上半年變動租金收益總額 (百萬港元)1,0291,115- 7.6%物業收益淨額(百萬港元)859954- 10.0%可分派收入(百萬港元)476544- 12.6% 每基金單位分派(港元)0.07010.0809- 13.3% 於2025年6月30日於2024年12月31日變動物業組合總值(百萬港元)58,09860,104- 3.3%每基金單位資產淨值(港元)6.797.16- 5.2%資產負債比率24.5%23.7%+ 0.8pp概覽2025年上半年,儘管全球經濟因貿易緊張局勢和地緣政治衝突而面對重重阻力,但香港的市場氣氛獲多項利好因素支持。股市回暖、香港銀行同業拆息於第二季回落,住宅銷售趨穩定,以及旅遊業穩步復蘇均有助抗衡外部壓力。然而,港人外遊熱潮未退,消費力外移令本地零售市道受壓。與此同時,寫字樓租賃市場依然淡靜,反映供求持續失衡。在此市況下,本信託的可分派收入下跌12.6%至4.76億港元,而每基金單位分派(「每基金單位分派」)則減少13.3%至0.0701港元。冠君產業信託行政總裁侯迅女士(左),冠君產業信託投資及投資者關係總監陸嘉萍女士(右)花園道三號雖然中環整體寫字樓市場的租賃動力仍然疲弱,但隨着金融市場轉趨活躍,我們接到的租賃查詢有所增加,需求主要來自金融相關企業。花園道三號落實引進一批新的租賃面積較小的租戶,包括家族辦公室;而一名現有銀行業租戶亦於物業內擴充。於2025年6月30日,花園道三號寫字樓的出租率為80.7%。該物業的租金收益期內減少5.4%至5.40億港元(2024年:5.71億港元)。我們持續推動續租工作,2025年到期的租約已全部處理完畢且續約率維持在高水平,當中包括多名主要租戶的續租。而2026年到期的租約亦有超過70%已續租。朗豪坊辦公樓報告期內,朗豪坊辦公樓推出名為「6D Wellness」的YouTube頻道,藉此強化朗豪坊辦公樓作為一站式身心健康及生活時尚總匯的市場定位。於2025年6月30日,在該物業的租戶組合中,生活時尚(身心健康)行業租戶佔比達68%。於2025年6月30日,朗豪坊辦公樓的出租率保持在86.9%的穩定水平。我們擴大了共享工作空間的營運規模並增設「Social Wellness Hall」,專為舉辦工作坊及交流活動而設,正好呼應辦公樓推廣身心健康的定位。市場租金繼續面對挑戰,租金收益因而減少9.1%至1.51億港元(2024年:1.66億港元)。冠君產業信託行政總裁侯迅女士朗豪坊商場今年迎接開業20周年的朗豪坊商場,繼續秉持「Stay Local,Trend Global」(「立足本地,引領全球潮流文化」)的願景。透過沉浸式體驗和限定商品,我們成功吸引破紀錄的人潮及推動銷售,並在八月刷新單日人流紀錄。近日,首次進軍香港的時裝品牌BENLAI,以及全城首家以生活風格為主題的期間限定店Umbro均在朗豪坊商場開業,人氣拉麵店Chiikawa Ramen Buta亦選址朗豪坊商場設立首家海外分店,旋即成為高人氣新熱點。於2025年6月30日,商場的出租率維持在99.2%的高水平,目前屬已承諾悉數租出的狀態。消費行為的改變為租戶帶來挑戰,租金收益跌至3.38億港元(2024年:3.78億港元)。分派本信託期內可分派收入下跌12.6% 至4.76億港元(2024年:5.44億港元),而每基金單位分派則減少13.3%至0.0701港元(2024年:0.0809港元)。按2025年6月30日的基金單位收市價2.08港元計算,相當於年度分派率6.7%。資產值於2025年6月30 日,本信託旗下物業組合的估值為581億港元,較2024年12月31日的601億港元減少3.3%。可持續發展我們繼續透過提升氣候抗禦力、建立有意義的聯繫及促進社區福祉,為我們的生態圈創造共享價值。報告期內,花園道三號引入人工智能製冷機組優化系統,全年節省大廈制冷設備的能源用量達6.1%。我們透過「綠『惜』環保約章」計劃,推動寫字樓和零售租戶攜手實現可量化的環保目標。此外,我們舉辦以「創新.啟發.融合」為主題的「冠君產業信託 ESG Gala」,凝聚逾千名租戶和商業夥伴,共同推進可持續營運及共融舉措。展望儘管香港零售業已重拾增長,金融市場亦見反彈,預料本信託於2025年後續期間的整體經營環境依然嚴峻。雖然港元利率回落有助節省利息支出,但續租租金下跌或將持續壓抑租金收益及令分派較去年為低。面對競爭激烈的市場環境,我們將繼續以靈活的營運策略積極應對。有關冠君產業信託(股份代號:2778)冠君產業信託擁有及投資提供租金收入的寫字樓及零售物業。信託主要投資位於優越地點的甲級商用物業。現時擁有花園道三號及朗豪坊兩幢位於香港的地標性物業,並以合資股權形式擁有位於倫敦市中心的 66 Shoe Lane,總樓面面積約300萬平方呎,讓投資者可直接投資於優質甲級寫字樓及零售物業。信託自2023年榮獲全球房地產GRESB可持續的最高五星級別。冠君產業信託管理人乃鷹君資產管理(冠君)有限公司,為鷹君集團的成員。網站: www.championreit.com Copyright 2025 亞太商訊 via SeaPRwire.com.
More
盈立集團積極擴張 開設12間分行 紮根香港新加坡 服務全球投資者 ACN Newswire

盈立集團積極擴張 開設12間分行 紮根香港新加坡 服務全球投資者

香港,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 由周大福控股戰略入股的uSMART盈立證券欣然宣佈香港落馬洲港鐵站、西九龍高鐵站分行已正式投入服務,涵蓋陸路出入境和高鐵樞紐客戶群。為隆重其事,盈立證券今日在西九龍分行舉行簡單而隆重的開幕儀式,並邀得不少財經界精英出席,令活動生色不少。開幕禮上,盈立證券執行董事李建翰先生 (Neo Lee) 表示:「為提供更便捷的金融服務予區內居民,盈立集團計劃年內於香港及新加坡兩地社區內開設分行,連同總部客戶專區,服務點增至12個,進駐尖沙咀、銅鑼灣、荃灣、上水及上環等核心地區,全面強化區域服務網絡,拉近與本地客戶的距離,提供更貼心的服務。」「作為港資科技券商No.1^,全球超過800,000用戶,盈立證券十分重視提升用戶的投資體驗,是次開立分行不但提供綜合服務,包括投資諮詢、辦理開戶等,還協助長者及初學者處理開戶流程、學習App使用方法等,藉此深化本地市場,滿足客戶對相關服務的殷切需求。」Neo Lee 續說。(左起︰盈立證券業務拓展總監鄧永麟先生、盈立證券香港市場部總監黃曉霖小姐、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券資產管理兼投研部總監蔣雄先生及盈立證券業務拓展經理林向尊先生)新張期內,前往分行打卡即可獲贈神秘禮品乙份,同時亦可免費享用飲料及手機充電服務,於分行開戶更可額外獲得豐富禮品。為進一步開拓香港市場,盈立證券推出「Trader賬戶」,香港本地客戶專享美港股一世免佣,美股期權0佣優惠。為感謝客戶的支持,uSMART盈立證券亦同時提供多項真全免優惠,不論新客戶或現有客戶,均可享受,絕無取巧,優惠包括:1)IPO 孖展認購0息│現金認購0手續費;2)>100隻港股ETF 0佣0平台費 (當中包括近期投資者熱愛的高息股ETF、虛擬資產相關ETF及指數ETF等);3)月供美股、港股0佣0平台費0存倉費及免代收股息稅以上優惠旨在滿足短線、中線及長線投資策略,讓持有uSMART盈立證券賬戶的客戶均能受惠。Neo Lee在開幕禮上透露,集團正積極增聘人手,擴充香港及新加坡團隊,以支持及推進業務發展,提高本地市場競爭力;而集團旗下的美國辦公室亦正式進駐至世界金融中心-紐約曼哈頓城中心,並將專注於對接對沖基金、家族辦公室及擬赴美上市企業,提供機構經紀、資產配置及投行諮詢等專業服務,鞏固全球金融科技券商領域的領先地位。展望未來,uSMART盈立證券秉持以客為本的理念,為更多本地投資者提供星級投資體驗及優質線下服務,同時亦致力推動金融服務的創新與升級,為全球客戶創造更多價值。^「港資科技券商No.1」是取自捷利金融雲截至2025年5月為止連續超過一年數據, uSMART 盈立證券為香港本地港資互聯網券商月成交總額排行第1。 優惠受條件及細則約束關於uSMART盈立證券:由周大福控股戰略入股的盈立證券是一間領先科技港資券商,成立於2018年,7年來憑藉卓越的戰略規劃和創新能力,致力於將科技與金融深度融合,業務範圍涵蓋證券、資產管理、財富管理等領域,為全球投資者獨家研發了金融證券交易平台uSMART HK APP和uSMART SG APP,分別由盈立證券(香港)和盈立證券(新加坡)提供服務。集團APP支持港股、美股、A股(滬深港通)、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務,此外更為超高淨值個人與家族、企業提供度身訂制服務,打造全方位綜合性資產管理解決方案。詳情可瀏覽https://hk.usmartglobal.com/傳媒查詢:黃曉霖Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亞太商訊 via SeaPRwire.com.
More
康哲藥業(867.HK,8A8.SG)上半年營收淨利雙升 戰略轉型跑出增長新動能 ACN Newswire

康哲藥業(867.HK,8A8.SG)上半年營收淨利雙升 戰略轉型跑出增長新動能

深圳,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 8月18日,康哲藥業發佈2025年中期業績,公司營收和利潤同比均實現增長,戰略轉型成效初顯。報告期內,公司實現營業收入約40.0億元(人民幣,下同),同比增長10.8%。若全按藥品銷售收入計算則營收約46.7億元,同比增長8.9%。實現淨利潤約9.3億元,同比增長3.1%。具體來看,康哲藥業已走出國採陰霾,業績將回歸持續上升軌道。公司主要非國採獨家/品牌產品及創新產品全按藥品銷售收入合計約29.0億元,同比增長20.6%,占總收入比重升至62.1%。公司獨家/品牌產品、創新產品競爭格局良好、增長可預期性強,目前已成為拉動業績向上的主力軍。根據業績公告,公司自2018年起擘畫「新康哲」轉型藍圖,以「產品創新、商業革新、國際拓展」三大戰略為支柱,構建可持續的第二增長曲線。行至2025年上半年,良好的經營業績及創新成果持續落地,證實戰略升級已逐步兌現為硬核戰果。「新產品」戰略推動創新價值兌現 夯實增長後勁立於公司三大戰略之首的「產品創新」戰略,依託「海外授權+國內合作+自主研發」三維創新機制,持續注入高價值短、中、長期管線,成為驅動增長的重要引擎。目前,創新戰略已進入持續收穫期,新產品正不斷釋放商業與臨床價值。截至目前,公司已有5款創新藥成功於中國實現商業化;2025年內,蘆可替尼乳膏和德昔度司他片兩款創新產品亦有望獲批上市。蘆可替尼乳膏是美國FDA以及歐洲EMA批准的首個、也是唯一一個局部JAK抑制劑非節段型白癜風複色產品,有望成為中國獲批上市的首款白癜風治療藥物,將填補市場空白,為中國白癜風患者帶來新希望。此外,阿爾茨海默病新藥ZUNVEYL的中國上市申請(NDA)亦已於今年7月獲受理;消費醫療產品注射用聚左旋乳酸微球填充劑已獲得上市批准,進一步豐富公司多元化產品矩陣。在研創新管線中,已有多款重磅候選藥物進入中國後期臨床開發階段,預計將在未來1-3年內陸續進入商業化,形成持續放量的新動力。其中,合作產品注射用Y-3已完成中國III期臨床,該產品為原創單分子1類新藥,亦為全球唯一進入臨床研究的非肽類PSD95/nNOS解偶聯劑,並有望成為首個治療缺血性卒中並預防卒中後抑鬱焦慮的雙功能腦細胞保護藥物。另一個口服小分子1類新藥ABP-671(URAT1抑制劑)用於治療痛風及高尿酸血症,目前其中國IIb/III期臨床正有序推進中。相較現有主流藥物,該產品有潛力以更低劑量將尿酸降低至更低水平,並具有溶解痛風石的能力,有望為患者提供療效更優、安全性更高的治療選擇。康哲藥業亦持續增厚創新儲備,不斷夯實全鏈條創新實力,以實現創新產品分階段、源源不斷獲批上市。2025上半年,公司新增ZUNVEYL、MG-K10(長效抗IL-4Rα人源化單抗注射液)兩款合作開發創新產品。截至目前,公司累計佈局約40款差異化創新管線,其中約20項為自主研發項目。同步推進「新模式」、「新地域」戰略 拓展多維增量空間根據業績公告,康哲藥業持續推進「新模式-商業革新」戰略,以多元生態鍛造抗週期韌性;並堅定執行「新地域-國際拓展」戰略,以產業國際化出海模式構建多維增長格局。在商業革新戰略下,公司持續聚焦專科領域,同時拓展新零售、新媒體渠道,構建「院內+院外」、「線上+線下」全覆蓋的營銷推廣體系,並持續強化消費醫療產品佈局。公司皮膚健康業務「德鎂醫藥」已在這一具消費屬性的賽道嶄露頭角,自2021年獨立運營以來,已實現皮膚疾病領域適應症覆蓋廣度、皮膚處方藥收入規模的雙重領先,將通過介紹上市、實物分派方式,擬分拆於香港聯交所主板獨立上市,進一步釋放其獨立價值與高成長潛力。國際化方面,2025年7月15日,公司以介紹方式成功於新加坡交易所完成第二上市,「產業國際化」戰略邁入新里程。以新加坡為樞紐,公司構建起覆蓋「研-產-銷」的新興市場全鏈條業務體系。截至目前,商業化平台公司Rxilient已在東南亞、中東、港澳台等地區累計提交近20款藥品和器械註冊申請,涵蓋皮膚科、眼科、腫瘤、自免、中樞神經等領域。蘆可替尼乳膏(白癜風適應症)已在澳門、香港獲批,並已遞交新加坡、台灣註冊申請;靜脈注射用特瑞普利單抗(首個被中國NMPA及美國FDA批准上市的國產抗PD-1單抗藥物)已提交馬來西亞等五國註冊申請;替瑞奇珠單抗注射液、蔗糖羥基氧化鐵咀嚼片亦在香港獲批。同時,公司持股45.0%的聯營CDMO生產工廠PharmaGend,目前已具備片劑、膠囊等口服固體製劑年產10億片的能力,並獲得新加坡HSA頒發的生產許可證、美國FDA cGMP認證及瑞士QP審計通過。PharmaGend鼻噴劑、乳膏、注射劑等新產線的建設正穩步推進中,為國際市場提供高標準生產交付能力。展望未來,「新康哲」增長邏輯有望加速兌現,盈利能力與業績韌性將同步提升。公司正構建以差異化創新為核心、多元生態協同驅動、國際化佈局支撐的增長體系,為高質量發展打開長期空間,為全球患者提供高品質醫藥產品和服務,為股東帶來可持續回報。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平台型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力,其中皮膚健康業務已成爲該細分領域的龍頭企業,帶來專科規模效率。同時,康哲藥業持續深化東南亞及中東區域業務發展,助力高質量持續健康發展。康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
China BlueChem Reports Revenue of RMB5.850 Billion and Profit of RMB641 Million for 2025 Interim ACN Newswire

China BlueChem Reports Revenue of RMB5.850 Billion and Profit of RMB641 Million for 2025 Interim

Financial Highlights:(RMB Million)For the Six Months Ended 30 June1H 20251H 2024% ChangeRevenue5,8506,007- 2.61%Gross Profit8481,003- 15.45%Profit Before Tax839899-6.67%Net Profit Attributable to Owners of the Company641687- 6.70%Basic Earnings per Share (RMB)0.140.15- 6.67%HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - China BlueChemical Ltd. (“China BlueChem” or the “Company,” stock code: 3983), China’s largest chemical fertilizer central enterprise in both production capacity and production volume, has announced its unaudited interim results for the six months ended 30 June 2025. In the first half of 2025, the Company realized a revenue of RMB 5.85 billion, slightly down by 2.6% year-on-yearly. Net profit attributable to owners of the Company amounted to RMB 641 million, a slight year-on-year decrease of 6.7%.Mr. RAO Shicai, CEO of China BlueChem said, “Despite the complex and volatile external environment and internal structural adjustment pressures, the Company’s key operating indicators have been successfully achieved. During the period, the Company has strengthened its safety production management, actively expanded its market and sales channels, and further developed lean management, while at the same time steadily implementing various measures to stabilize growth, reinforce reforms, and enhance efficiency Moreover, the Company has consistently adhered to a philosophy of green and sustainable development. Its methanol plant has been awarded the honorary title of “Energy Efficiency Leader” by the China Petroleum and Chemical Industry Federation for 14 consecutive years, and its synthetic ammonia plant has been awarded the honorary title of “Water Efficiency Leader” by the China Nitrogen Fertilizer Industry Association for 6 consecutive years. It also won the “2025 ESG Model Enterprise Award” at the 4th International Green Zero-Carbon Festival and ESG Leadership Summit, setting a benchmark for sustainable development brands.”In respect of production management, the Company continuously strengthened production and operation control and system management, thoroughly implementing the concept of green development and stable safety production conditions. During the period, methanol production at CNOOC Fudao and the cumulative throughput at Basuo Port both reached new highs for corresponding periods in history. The CNOOC Huahe Chemical Fertilizer Plant achieved 314 days of continuous operation, making a new record of itself and setting outstanding production indicators. In the first half of the year, the Company produced 968,000 tonnes of urea, 781,000 tonnes of methanol, 450,000 tonnes of phosphate fertilisers and compound fertilizers, and 132,000 tonnes of acrylonitrile series products.With regard to sales management, amidst the complex and ever-changing market situation, the Company has continued to further strengthen market analysis and keep up with the market to implementprecise pricing. By solidifying the weekly production and sales coordination meeting mechanism, the Company has optimised storage and transportation coordination, and ensured efficient product circulation., It has also comprehensively advanced market expansion and efficiency improvements. In the first half of the year, the Company sold 996,000 tonnes of urea, 726,000 tonnes of methanol; 386,000 tonnes of phosphate fertilizers and compound fertilizers, and 127,000 tonnes of acrylonitrile series products.As for green development, the Company accelerated the implementation of key projects, successfully producing the first tonne of green methanol in China using urban waste as raw material, and obtaining International Sustainability and Carbon Certification (ISCC) in the first half of the year. The green methanol has been successfully applied to domestically produced dual-fuel vessels, marking the first domestic use of green methanol. Furthermore, the Company achieved unified integration of monitoring data into the environmental protection information system, with pollutant emissions meeting standards at 100% for three consecutive years, and the number of environmental pollution incidents remaining at zero. The comprehensive utilization rate of phosphogypsum at DYK increased from 61.15% to 73.09%, exceeding the target requirements.Looking ahead to the second half of the year, urea will remain in a capacity expansion cycle and the overall market will continue to be oversupplied. In the third quarter, demand will be stronger driven by the combined impact of the export window and agricultural demand. Entering the fourth quarter, the release of new capacity and weakening demand will create a ripple effect, and prices are expected to remain under pressure. The prices of monoammonium phosphate may fluctuate within a narrow range at a high level, supported by strong raw material costs and favorable demand factors. The diammonium phosphate market is expected to maintain a stable consolidation cycle. In the third quarter, domestic autumn storage and export demand will resonate, resulting in strong overall demand and stable prices. In the fourth quarter, the demand for phosphate fertilizer is expected to decline overall, putting downward pressure on prices, but overall fluctuations will be relatively limited, supported by cost factors. In the second half of the year, the trend of methanol supply is expected to remain accommodative. Benefited from anti-involution in mainland China and the restriction policy on new coal-to-methanol projects, the supply and demand structure is expected to be improved. Downstream demand may see a phased recovery, with the overall market trend characterized by fluctuations. Regarding acrylonitrile, the oversupply situation will further intensify. Any improvement in acrylonitrile prices will require major domestic companies to reduce plant loads.Mr. RAO Shicai, CEO of China BlueChem said, “In the second half of 2025, the Company will refine its equipment management system to ensure safe and stable operation of facilities and establish a solid foundation for intrinsic safety. At the same time, it will focus on establishing its quality positioning, expanding market and sales, and enhancing marketing effectiveness. "AI+" initiatives will be promoted across the Company to accelerate the deep integration of digital technology and the real economy. In addition, the Company will push forward the study of key projects on the utilization of carbon-rich natural gas and strengthen communication matrix management to continuously enhance brand value.”About China BlueChemical Ltd.China BlueChemical Ltd. (“China BlueChem”) is a listed company that specialises in the development, production and sales of chemical fertilisers and synthetic chemical products. It is the largest Central enterprise in the field of chemical fertilisers in terms of both production capacity and production volume. The Company is a subsidiary of China National Offshore Oil Corporation which mainly engages in the exploration, development, production and sales of crude oil and natural gas. On 29 September 2006, China BlueChem was listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 3983. Currently, its production facilities are located in Hainan, Hubei and Heilongjiang, China, with a total designed annual production capacity of 1.84 million tonnes of urea, 1.3 million tonnes of phosphate and compound fertilisers (mono-ammonium phosphate, di-ammonium phosphate and compound fertiliser), 1.4 million tonnes of methanol, 200 thousand tonnes of acrylonitrile and 70 thousand tonnes MMA. It has a deep water port with a designed annual throughout capacity of 18.28 million tonnes in Dongfang city, Hainan province. Boasting continued growth of its brand value, the Company’s brand value reached historical high at RMB7.258 billion in 2025. Besides, the Company was awarded “ËSG Model Enterprise 2025” at the 4th International Green Zero-Carbon Festival Cum ESG Leaders Conference.For more information about the Company, please visit its website:www.chinabluechem.com.cn. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
中海石油化學2025年中期實現收入人民幣58.50億元 盈利人民幣6.41億元 ACN Newswire

中海石油化學2025年中期實現收入人民幣58.50億元 盈利人民幣6.41億元

財務摘要(人民幣億元)截至 6 月 30日止年度2025年中期2024年中期變動收入58.5060.07- 2.61%毛利8.4810.03- 15.45%稅前利潤8.398.99-6.67%本公司擁有人應佔淨利潤6.416.87- 6.70%每股基本盈利 (人民幣元)0.140.15- 6.67% 香港,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 中海石油化學股份有限公司(「中海石油化學」或「公司」,股份編號:3983) 公佈截至2025年6月30日止日止半年度未經審計之業績。2025年上半年公司實現收入人民幣5,850百萬元,同比微跌2.6%,本公司擁有人權益應佔淨利潤為人民幣641百萬元,同比微跌6.7%。中海石油化學首席執行官饒仕才先生表示:「縱使面對外部環境複雜多變與內部結構調整壓力,公司主要經營指標仍然完成良好。期内,公司繼續強化安全生產管理,積極拓展市場與銷售渠道,深化精益管理;同時,扎實推進穩增長、深改革、提效能各項工作。此外,公司堅持秉持綠色可持續發展理念,甲醇裝置連續十四年獲評石化聯合會『能效領跑者』榮譽稱號,合成氨裝置連續六年蟬聯氮肥協會『水效領跑者』 榮譽稱號,並榮膺第四屆國際綠色零碳節暨ESG領袖峰會『2025 ESG 典範企業獎』,樹立了可持續發展品牌標杆。」生産管理方面,公司持續強化生產經營管控與體系管理,深入踐行綠色發展理念,安全生產形勢總體平穩。期内,海南富島甲醇產量與八所港累計吞吐量均創歷史同期新高,華鶴煤化工化肥裝置實現314天長週期運行,刷新自身紀錄,生產指標表現亮眼。上半年,公司生產尿素96.8萬噸、甲醇78.1萬噸、磷肥及複合肥45.0萬噸、丙烯腈系列產品13.2萬噸。銷售管理方面,面對複雜多變的市場形勢,公司持續深化市場研判,緊貼市場精準定價。通過固化產銷協同周例會機制,優化儲運銜接,保障產品高效流通。同時加大出口創效力度,全面推進拓市增效。上半年,公司銷售尿素99.6萬噸、甲醇72.6萬噸、磷肥及複合肥38.6萬噸、丙烯腈系列產品12.7萬噸。綠色發展方面,上半年公司加速推進重點項目落地,成功產出以城市垃圾為原料的國內首噸綠色甲醇,並獲得國際可持續發展和碳認證(ISCC)。該產品成功應用於國產雙燃料船舶,實現了國內綠色甲醇首次加注。此外,公司實現監測數據統一接入環保資訊系統,污染物排放連續三年100%達標,環保污染事故事件保持為零。其中,大峪口化工磷石膏綜合利用率由61.15%提升至73.09%,超額完成指標要求。展望2025下半年,尿素仍處於產能擴張週期,市場整體將延續「供大於求」格局,三季度受出口窗口期與農需支撐疊加影響,需求較強;進入四季度後,新增產能釋放與需求轉淡形成共振,價格預計持續承壓。磷酸一銨價格或呈高位窄幅震盪態勢,一方面原料成本支撐強勁,另一方面需求端亦有利好因素加持。磷酸二銨市場預計維持穩中整理節奏,三季度國內秋儲與出口需求共振,整體需求旺盛,價格將保持平穩運行;四季度磷肥需求預計整體回落,價格存在回調壓力,但受成本端支撐,整體波動幅度將較為有限。預計下半年,甲醇供應延續寬鬆態勢,受益於國內反內捲及煤製甲醇新建項目政策限制,供需結構有望改善,下游需求或呈階段性回暖,市場整體走勢以震盪為主。丙烯腈方面,供過於求的格局預計將進一步加劇,丙烯腈價格若要出現好轉,需依賴國內主流企業降低裝置負荷。公司首席執行官饒仕才先生表示:「2025年下半年,公司將聚焦完善設備管理體系,保障裝置安全平穩運行,夯實本質安全基礎;同時著力打造品質定位,抓好拓市拓銷,提升營銷創效能力。此外,公司將推進『人工智慧+』行動,加速數智技術與實體經濟的深度融合,推動富碳天然氣利用重點項目研究及強化傳播矩陣管理,持續提升品牌價值。」有關中海石油化學股份有限公司中海石油化學股份有限公司(「中海石油化學」)是專門從事化肥及相關化工産品開發、生産及銷售的上市企業,是化肥産能及産量最大的中央企業,為從事石油和天然氣勘探、開發、生産及銷售的中國海洋石油集團有限公司之子公司。中海石油化學於2006年9月29日在香港聯合交易所主板掛牌上市,股份編號:3983。公司現有生産設施位於中國海南、湖北及黑龍江,總設計年産能達184萬噸尿素、130萬噸磷複肥(磷酸一銨、磷酸二銨和複合肥)、140萬噸甲醇、20萬噸丙烯腈及7萬噸MMA,公司並擁有位於海南省東方市的設計年吞吐能力為1,828萬噸的深水港口。中海石油化學的企業品牌價值持續提升,2025年達72.58億元,創歷史新高。2025年,中海石油化學榮膺第四屆國際綠色零碳節暨ESG領袖峰會『2025 ESG 典範企業獎』。如欲查詢更多公司資料,請瀏覽公司網站 www.chinabluechem.com.cn。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More

Qunabox Group Deliver Strong H1 2025 Performance with Over 30% Growth in Revenue and Gross Profit

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, the artificial intelligence (AI) sector emerged as one of the most prominent structural investment themes in capital markets, sparking significant market enthusiasm. The market capitalization of leading companies in multiple AI-related segments saw significant increases, and the overall sector valuation rose markedly. As a result, the AI sector has become a high-prosperity track favored by institutional investors for portfolio allocation.Market analysts expect AI applications to emerge as a breakout sector as artificial intelligence deepens its integration across industries. Companies demonstrating both product innovation and real-world deployment capability are likely to draw heightened investor appetite. Among them, Qunabox Group (00917.HK), with its forward-looking strategic layout in “AI + Consumption Scenarios,” along with sustained high-intensity investment in technology and strong product commercialization capabilities, is poised to stand out in this wave of technology-scenario integration, potentially establishing itself as one of the most promising growth companies in this sector.On August 15, Qunabox Group released its 2025 interim results. In the first half of 2025, the Company achieved robust growth driven by continuous advancements in business model innovation, service capabilities enhancement, industry reputation building, and improved team execution. Leveraging its competitive advantages accumulated through years of sustained investment in AI, Qunabox Group seized the policy-driven opportunities in AI and consumption industries. The Company achieved revenue of RMB676.2 million, representing a year-on-year increase of 31.3%, while gross profit rose to RMB385.5 million, up 37.0% year-on-year, maintaining strong growth momentum and solidifying the Company’s leading position in China’s AI interactive marketing industry.Strategic Upgrade: Comprehensive Industrial Expansion from AI+ Marketing to AI+ Consumption ScenariosIn response to the profound transformation brought by the AI industrial revolution, Qunabox Group has fully upgraded its core strategy to focus on “AI + Consumption Scenarios”. The Company is concentrating on two key application scenarios – AI+ Marketing and AI+ Entertainment – while accelerating innovation in AI-powered services and product development. To support this strategic shift, the Company significantly increased its research and development investment in the first half of 2025 to RMB77.8 million, representing a year-on-year growth of 107.7%. As of 30 June 2025, Qunabox Group has established a robust technological moat, with cumulative registrations of 159 software copyrights and 34 patent applications.In terms of technology research and development, Qunabox Group has built an AI technology middle platform that reinforces its foundational technical architecture. By innovatively adopting a modular design approach, the Company has developed a reusable AI capabilities pool, significantly enhancing research and development efficiency and strengthening the scalability of its technologies across diverse application scenarios. Meanwhile, its self-developed multi-modal neural integrated collaborative engine—the AI-OMNI Engine (AI-Orchestrated Multimodal Neural Integration) —has achieved key technological breakthroughs, successfully empowering the three core layers of “perception, decision, execution,” significantly enhancing edge intelligence and multi-scenario adaptability.Notably, Qunabox Group has also made forward-looking advancements in the field of AI Agent. According to the Company’s 2025 interim report, it has deeply integrated AI Agent technology with its self-developed terminal operation and maintenance (O&M) large model, establishing a more intelligent O&M management system. This technological integration not only enables intelligent task dispatching and automated maintenance guidance, but also drives the transformation of O&M models from traditional “reactive maintenance” to “proactive prevention.” Industry analysts believe this move significantly enhances the professional capabilities and execution efficiency of terminal operation teams, marking a critical step in Qunabox Group’s journey toward operational intelligence. Moreover, it provides solid operational support for the large-scale implementation of the company’s “AI + Consumer Scenarios” strategy.Rapid Unleashing of the “AI+ Marketing” Business Flywheel EffectIn terms of marketing business, Qunabox Group has built a high-growth business flywheel by continuously driving the coordinated evolution of five core elements including product, client, data, technology and operations. In the first half of 2025, Qunabox Group’s marketing service revenue reached RMB568.0 million, representing a year-on-year increase of 37.9%; gross profit was RMB353.3 million, up 43.8% year on year. Among these, revenue from the standardized marketing services segment increased by 34.3% year on year, while revenue from the high-margin value-added marketing services segment grew by 63.1%, effectively boosting the Company’s overall profitability.On the one hand, while maintaining strong and stable partnerships with brand customers, Qunabox Group further tapped into the potential of KA customers by expanding service application scenarios, enriching and optimizing AI interactive marketing products, developing data strategy products, and refining its marketing product portfolio and service pattern, thereby broadening its collaboration with major customers. Leveraging its proprietary AI-OMNI Multi-modal Neural Synergy Engine, the Company has achieved dual breakthroughs in AI digital shopping assistants—enhancing both intelligent interaction capabilities and visual expressiveness—thereby significantly boosting customer engagement and conversion rates at offline terminals. In the first half of 2025, the average revenue per KA customer increased to RMB16.2 million, representing a year-on-year growth of 52.2%, providing strong support for high-quality revenue growth. On the other hand, by leveraging its technological and operational capabilities to advance the modularization of its marketing system, the Company enhanced its flexible combination capabilities between standardized marketing services and value-added marketing service modules, enabling complementary synergy, flexible integration, and efficient reuse between standardized and value-added services.It can be said that Qunabox Group’s “AI + Marketing” strategy has evolved from technological leadership to systematic growth, forging a five-dimensional moat integrating products, clients, data, technology, and operations—laying a robust foundation for sustained future growth.“AI+ Entertainment” Goes Global: Middle East Expansion Marks the Start of Ambitious Worldwide GrowthIn addition to marketing scenarios, Qunabox Group is actively capitalizing on the emerging “emotional consumption” trend in expanding the boundaries of AI entertainment applications. The Company has strategically positioned “AI + Entertainment” as a new frontier, aiming to build world-leading AI-powered indoor entertainment spaces, with the Middle East market as its first stop for global expansion. In the first half of 2025, Qunabox Group established an Overseas Entertainment Division, focusing on the strategic planning, product design, and commercialization of AI indoor entertainment spaces, to further strengthen the execution efficiency and market expansion of this business.Currently, the Division has completed its organizational structure and preparation for the first batch of venues, successfully obtaining the relevant local licenses. At the same time, core tasks such as product design and optimization, software and hardware system development, and the construction of content ecosystems are steadily progressing. Industry experts suggest this move may represent a strategic play in Qunabox Group’s global “IP incubation” initiative. By leveraging AI-generated technology and deep user behavior insights, the Company could develop original virtual characters and interactive experiences that balance local cultural relevance with global appeal. Through cross-media storytelling and digital asset management, these efforts may cultivate high-value original IPs. Such IPs are expected to serve as the core driver for AI entertainment spaces while extending into diverse monetization scenarios—including digital merchandise, brand collaborations, and fan engagement—significantly enhancing both user retention and commercial potential.In addition, Qunabox Group will deepen its diversification layout around the “AI + Consumption Scenarios” strategy. Through strategic acquisitions and ecosystem synergies, the Company will systematically extend its business boundaries and value chain depth to achieve high-quality, scalable growth.From a medium-to-long-term perspective, AI will continue to be the core driving force of industrial transformation, accelerating its penetration into marketing, entertainment, retail, and other scenarios. As a leading company in AI consumption scenarios, Qunabox Group remains at the forefront of AI industry applications through continuous strategic upgrades, technological innovation, and product implementation, building a long-term, sustainable, and high-quality growth flywheel. With the ongoing advancement of its “AI + Consumption Scenarios” strategy, Qunabox Group will unlock new frontiers for innovative growth. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Focus Graphite Announces Board Changes and Upcoming International Trade Mission with Natural Resources Canada ACN Newswire

Focus Graphite Announces Board Changes and Upcoming International Trade Mission with Natural Resources Canada

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange ACN Newswire

Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.
More
CENTRESTAGE 10th anniversary set to dazzle in September ACN Newswire

CENTRESTAGE 10th anniversary set to dazzle in September

- Some 260 brands from 24 countries and regions set to participate, a new high for the event, with the UK debuting as Partner Country to present works by leading British designers- Internationally acclaimed couturier Guo Pei will stage her first solo couture show in Hong Kong, unveiling 30 meticulously crafted pieces under the theme “Gilternity: An Everlasting Radiance”- Aligning with market trends, the fair will introduce a new Accessories Zone and will once again feature the Circular Fashion Zone to promote the development of sustainable fashion- The Fashion Hong Kong Runway Show will celebrate the creative journey of local brands; around 30 fashion shows will be staged during the fair – the highest number in the event’s historyHONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. The four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The 2025 CENTRESTAGE exhibition will feature some 260 brands from 24 countries and regions – the largest brand lineup in the event’s history.The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com.
More